Mateu-Arrom, L, Martin, R, Expósito-Serrano, V, Alvarez-Abella, A, Serra-Baldrich, E, Spertino, J. Azathioprine for the Treatment of Chronic Spontaneous Urticaria Refractory to Antihistamines, Omalizumab, and Ciclosporin: A Case Series. Actas Dermo-Sifiliograficas. 2025; 116(8)DOI:10.1016/j.ad.2025.05.022. PMID:40480489. IF:(Q/D).

Feldman, SR, Sanz, LP, Girolomoni, G, Jo, SJ, Jung, H, Jung, J. Similarity of efficacy of SB17 to reference ustekinumab for moderate-to-severe psoriasis through 12 weeks in different demographic and comorbidity subgroups. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2025; 93(3)DOI:. PMID:. IF:11.800(Q1/1D).

Lebwohl, M, Langley, RG, Strober, B, Thaçi, D, Armstrong, A, Gordon, KB, Puig, L, Davies, O, Peterson, L, Davis, L, Warren, RB. Bimekizumab achievement of 'super response' using a previously published definition in moderate to severe plaque psoriasis: Results from four phase 3/3b trials. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2025; 93(3)DOI:. PMID:. IF:11.800(Q1/1D).

Contieri, R, Martini, A, Beijert, IJ, Mertens, LS, Hentschel, AE, Brundl, J, Compérat, EM, Plass, K, Rodríguez, O, Henríquez, JDS, Hernández, V, de la Pena, E, Alemany, I, Turturica, D, Pisano, F, Soria, F, Capoun, O, Bauerova, L, Pesl, M, Bruins, HM, Runneboom, W, Herdegen, S, Breyer, J, Brisuda, A, Calatrava, A, Rubio-Briones, J, Seles, M, Mannweiler, S, Bosschieter, J, Kusuma, VRM, Ashabere, D, Huebner, N, Seisen, T, Claps, F, Masson-Lecomte, A, Liedberg, F, Cohen, D, Lunelli, L, Cussenot, O, El Sheikh, S, Volanis, D, Cote, JF, Roupret, M, Haitel, A, Shariat, SF, Mostafid, AH, Nieuwenhuijzen, JA, Zigeuner, R, Dominguez-Escrig, JL, Hacek, J, Zlotta, AR, Burger, M, Evert, M, van de Kaa, CA, van der Heijden, AG, Kiemeney, LALM, Soukup, V, Molinaro, L, Hurle, R, Paciotti, M, Moschini, M, Pradere, B, Perdona, S, Gontero, P, Llorente, C, Algaba, F, Palou, J, N'Dow, J, Ribal, MJ, van der Kwast, TH, Babjuk, M, Sylvester, RJ, van Rhijn, BWG. Towards Defining Follow-up Strategies for Patients with Primary Intermediate-risk Non-muscle-invasive Bladder Cancer. European Urology Oncology. 2025; 8(4)DOI:10.1016/j.euo.2025.04.010. PMID:40399193. IF:9.300(Q1/1D).